Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03584399
Other study ID # 1802247905
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date March 1, 2019
Est. completion date December 31, 2020

Study information

Verified date April 2023
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Advances in modern medicine and critical care interventions have greatly impacted survival of critically ill patients, but these interventions are not without consequences. Although patients may now survive the initial critical illness, these patients may not recover to their pre-illness baseline state of health. Recent data in both the critically ill adult and neonatal patients who survive sepsis or surgical events have been shown to progress to persistent inflammatory, immunosuppressed, catabolic syndrome (PICS). This was first identified in adult trauma patients, and more recently was defined in critically ill neonates. To date, there are no published reports of PICS in the critically ill pediatric population. Our long-term goal is to understand PICS in the pediatric population and how early medical and nutritional interventions may impact overall morbidity and survival. To achieve this goal first PICS must first be characterized in the pediatric population. The hypothesis is that PICS occurs in pediatric patients and is associated with increased time to return to a baseline functional life post-injury or illness. The hypothesis will be tested by pursuing the following specific aims. Specific Aim 1: To determine the incidence of PICS in the pediatric population and associate the diagnosis of PICS to survival and time to return to baseline functional life and Specific Aim 2: To determine if early increased inflammatory and immunosuppressive markers are associated with the development of PICS and increased morbidity and mortality. These aims will be accomplished by conducting a prospective single-center observational pilot study to enroll pediatric patients with an anticipated pediatric intensive care unit (PICU) stay greater than 14 days. Through these two aims, the investigators anticipate that this research will provide an explanation into the interplay of inflammation, immunosuppression, and catabolism in critically ill children, which is imperative to the development of early therapeutic and nutritional interventions that can reduce morbidity and mortality associated with critical illness.


Description:

The long-term goal of this study is to understand PICS in the pediatric population and how early medical and nutritional interventions may impact overall morbidity and survival, but first PICS must be characterized in the pediatric population. The hypothesize is that PICS occurs in pediatric critically ill patients and is associated with increased time to return to a baseline functional life post-injury or illness. Enrollment/Randomization This is a prospective observational study with no randomization. The patients will be approached between PICU stay days 9-12 for consent. Labs will be drawn between PICU stay days 12-16 with a preference for PICU day 14, however, labs will be drawn in accordance with the standard of care labs to avoid additional draws. Study Procedures Specific Aim 1: To determine the incidence of PICS in the pediatric population and associate the diagnosis of PICS to survival and time to return to baseline functional life. In order to determine the incidence of PICS in PICU patients, a prospective single-center study will be conducted of all critically ill pediatric patients admitted to PICU at Riley Hospital for Children at Indiana University Health, Indianapolis, IN. Patients will be included if they have an anticipated stay of >14 days in the PICU. Patients will be excluded from this study if they have are maintained on chronic mechanical ventilation, have a known chronic inflammatory disease process, or are diagnosed with failure to thrive or malnutrition upon admission to the PICU. Data to be collected will include demographic data, nutrition data (weight, protein/non-protein calories received, type of nutrition and prescribed goal nutrition by a dietician), severity of illness, length of stay in the PICU and hospital. Existing routine labs from admission and PICU stay including blood counts, electrolytes and nutrition labs will be collected. At 14 days (± 1 day) the patient will be approached for inclusion into the study. At that time, routine labs to check for inflammation and nutritional status such as CRP, total lymphocyte count, albumin, prealbumin, and retinol binding protein will be collected Diagnosis of PICS will be determined when a patient has been admitted to the PICU for >14 days and has signs of both inflammation (CRP >15mg/L) and immunosuppression (total lymphocyte count < 0.80×109/L), as well as catabolism (Serum albumin < 3.0g/dL, Prealbumin <10mg/dL, Retinol binding protein <10μg/dL, and weight loss >10% or body mass index <18 during hospitalization). Data Management: Data will be entered and stored in in a de-identified/HIPAA compliant manner using a password protected web-based database that has securities to protect confidentiality and data integrity. The database will be constructed in REDCap. Data Analysis Plan: Clinical risk factors will be summarized and distributions examined. Relationships between the variables and the development of PICS will be explored using plots, correlation coefficients, and contingency tables. The association between clinical variables, including nutritional interventions, and PICS will then be analyzed with logistic regression. Both univariate and multivariate analyses will be conducted. The significance threshold p-value is set at 0.05. Specific Aim 2: To determine if early increased inflammatory and immunosuppressive markers are associated with the development of PICS and increased morbidity and mortality. Sample management and processing: In addition to CRP and TLC, which will be collected at 14 days (± 1 day) of PICU admission , additional blood samples will be collected at these time points to be frozen for further analysis. At the time of blood collection, an additional 5 mL of blood will be collected, processed, and stored at -80 degree Celsius. Once desired time-points are identified and further funding obtained, samples will be processed in batches to evaluate biochemical markers of inflammation. This will be performed using The Inflammatory Cytokine Human Magnetic 5-Plex Panel for the Luminex™ platform. This will quantify GM-CSF, IL-1β, IL-6, IL-8 and TNF-α in serum samples. The expected outcomes will focus on characterizing PICS in the pediatric population and identifying early inflammatory markers that may correlate with the development of PICS and subsequently increased morbidity associated with critical illness. The results are expected to have a positive impact by filling a key gap in the understanding of the mechanism of PICS in critically ill children. This research will provide insight into the interplay of inflammation, immunosuppression, and catabolism in critically ill children, which is imperative to the development of early therapeutic and nutritional interventions that can reduce morbidity and mortality associated with critical illness.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date December 31, 2020
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender All
Age group N/A to 18 Years
Eligibility Inclusion Criteria: - Patients who are < or = to 18 years of age and have an anticipated length of PICU stay of > or = to 14 days from June 1, 2018 through January 31, 2019 Exclusion Criteria: - Chronic mechanical ventilation, Known chronic inflammatory disease process, or Diagnosed with failure to thrive or malnutrition upon admission to the PICU

Study Design


Related Conditions & MeSH terms


Intervention

Other:
PICS in critically ill pediatric population
Collection of additional blood sample from those subjects meeting criteria for the study.

Locations

Country Name City State
United States Riley Hospital for Children Indianapolis Indiana

Sponsors (2)

Lead Sponsor Collaborator
Indiana University American Society for Parenteral and Enteral Nutrition

Country where clinical trial is conducted

United States, 

References & Publications (5)

Ellis N, Hughes C, Mazurak V, Joynt C, Larsen B. Does Persistent Inflammatory Catabolic Syndrome Exist in Critically Ill Neonates? JPEN J Parenter Enteral Nutr. 2017 Nov;41(8):1393-1398. doi: 10.1177/0148607116672621. Epub 2016 Oct 10. — View Citation

Epstein D, Brill JE. A history of pediatric critical care medicine. Pediatr Res. 2005 Nov;58(5):987-96. doi: 10.1203/01.PDR.0000182822.16263.3D. Epub 2005 Sep 23. — View Citation

Gentile LF, Cuenca AG, Efron PA, Ang D, Bihorac A, McKinley BA, Moldawer LL, Moore FA. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg. 2012 Jun;72(6):1491-501. doi: 10.1097/TA.0b013e318256e000. — View Citation

Marshall JC. Critical illness is an iatrogenic disorder. Crit Care Med. 2010 Oct;38(10 Suppl):S582-9. doi: 10.1097/CCM.0b013e3181f2002a. — View Citation

Vanzant EL, Lopez CM, Ozrazgat-Baslanti T, Ungaro R, Davis R, Cuenca AG, Gentile LF, Nacionales DC, Cuenca AL, Bihorac A, Leeuwenburgh C, Lanz J, Baker HV, McKinley B, Moldawer LL, Moore FA, Efron PA. Persistent inflammation, immunosuppression, and catabolism syndrome after severe blunt trauma. J Trauma Acute Care Surg. 2014 Jan;76(1):21-9; discussion 29-30. doi: 10.1097/TA.0b013e3182ab1ab5. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of PICS in the pediatric critical care population Diagnosis of PICS will be determined when a patient has been admitted to the PICU for >14 days and has signs of both inflammation (CRP >15mg/L) and immunosuppression (total lymphocyte count < 0.80×109/L), as well as catabolism (Serum albumin < 3.0g/dL, Prealbumin <10mg/dL, Retinol binding protein <10µg/dL, and weight loss >10% or body mass index <18 during hospitalization). July 1, 2018 to June 30, 2019
Secondary Mortality Death in the ICU associated with PICS July 1, 2018 to June 30 2019
See also
  Status Clinical Trial Phase
Recruiting NCT05864833 - METabolism After Orthopedic Surgery
Completed NCT02235961 - Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects Phase 1
Completed NCT02918279 - Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity Phase 3
Completed NCT00978393 - A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers Phase 1
Completed NCT03661879 - Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity Phase 1
Completed NCT05024032 - A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) Phase 3
Completed NCT02568306 - A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects Phase 1
Completed NCT00781937 - Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance Phase 3
Completed NCT03223493 - Awareness, Care & Treatment in Obesity Management (ACTION) Study
Completed NCT03308721 - Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity Phase 1
Completed NCT02941042 - A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity. Phase 1
Completed NCT02453711 - Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus Phase 2
Completed NCT02527200 - Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome Phase 3
Completed NCT02958085 - Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight Phase 1
Terminated NCT00665665 - Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers Phase 1
Completed NCT04156165 - The Effect of High vs. Moderate Protein Consumption on Human Health N/A
Recruiting NCT03669809 - The Biological Rhythm of Human Metabolite
Completed NCT02079870 - Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo Phase 1
Completed NCT03095807 - Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity Phase 1
Recruiting NCT05785221 - Lifestyle Intervention on Metabolic Homeostasis N/A